Precigen, Inc. operates as a biopharmaceutical company. The Company develops gene and cell therapies to target the diseases in immuno-oncology, autoimmune disorders, and infections. Precigen serves customers worldwide.

Quarterly Report (Form 10-Q | Period ending 2025-09-30)

Current Report (Form 8-K | Period ending 2025-11-13)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Precigen (PGEN US)

Quarterly Report (Form 10-Q | Period ending 2025-09-30)

Current Report (Form 8-K | Period ending 2025-11-13)

Current Report (Form 8-K | Period ending 2025-09-15)

Current Report (Form 8-K | Period ending 2025-09-03)

S-3 | Registration statement for specified transactions by certain issuers

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)